590 related articles for article (PubMed ID: 22406878)
1. Evaluation of costs associated with tolvaptan-mediated hospital length of stay reduction among US patients with the syndrome of inappropriate antidiuretic hormone secretion, based on SALT-1 and SALT-2 trials.
Dasta JF; Chiong JR; Christian R; Lin J
Hosp Pract (1995); 2012 Feb; 40(1):7-14. PubMed ID: 22406878
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of costs associated with tolvaptan-mediated length-of-stay reduction among heart failure patients with hyponatremia in the US, based on the EVEREST trial.
Chiong JR; Kim S; Lin J; Christian R; Dasta JF
J Med Econ; 2012; 15(2):276-84. PubMed ID: 22111754
[TBL] [Abstract][Full Text] [Related]
3. An economic analysis of tolvaptan compared with fluid restriction among hospitalized patients with hyponatremia.
Ramamohan V; Mladsi D; Ronquest N; Kamat S; Boklage S
Hosp Pract (1995); 2017 Aug; 45(3):111-117. PubMed ID: 28449624
[TBL] [Abstract][Full Text] [Related]
4. Tolvaptan use in cancer patients with hyponatremia due to the syndrome of inappropriate antidiuretic hormone: a post hoc analysis of the SALT-1 and SALT-2 trials.
Gralla RJ; Ahmad F; Blais JD; Chiodo J; Zhou W; Glaser LA; Czerwiec FS
Cancer Med; 2017 Apr; 6(4):723-729. PubMed ID: 28251822
[TBL] [Abstract][Full Text] [Related]
5. Randomized, double blinded, placebo-controlled trial to evaluate the efficacy and safety of tolvaptan in Chinese patients with hyponatremia caused by SIADH.
Chen S; Zhao JJ; Tong NW; Guo XH; Qiu MC; Yang GY; Liu ZM; Ma JH; Zhang ZW; Gu F
J Clin Pharmacol; 2014 Dec; 54(12):1362-7. PubMed ID: 24906029
[TBL] [Abstract][Full Text] [Related]
6. Treatment of hypervolemic or euvolemic hyponatremia associated with heart failure, cirrhosis, or the syndrome of inappropriate antidiuretic hormone with tolvaptan: a clinical review.
Nemerovski C; Hutchinson DJ
Clin Ther; 2010 Jun; 32(6):1015-32. PubMed ID: 20637957
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of tolvaptan for the treatment of hyponatraemia secondary to syndrome of inappropriate antidiuretic hormone secretion in Sweden.
Jamookeeah C; Robinson P; O'Reilly K; Lundberg J; Gisby M; Ländin M; Skov J; Trueman D
BMC Endocr Disord; 2016 May; 16(1):22. PubMed ID: 27184496
[TBL] [Abstract][Full Text] [Related]
8. Economic impact of tolvaptan treatment vs. fluid restriction based on real-world data among hospitalized patients with heart failure and hyponatremia.
Dasta JF; Sundar S; Chase S; Lingohr-Smith M; Lin J
Hosp Pract (1995); 2018 Oct; 46(4):197-202. PubMed ID: 30045645
[TBL] [Abstract][Full Text] [Related]
9. Rapidity of Correction of Hyponatremia Due to Syndrome of Inappropriate Secretion of Antidiuretic Hormone Following Tolvaptan.
Morris JH; Bohm NM; Nemecek BD; Crawford R; Kelley D; Bhasin B; Nietert PJ; Velez JCQ
Am J Kidney Dis; 2018 Jun; 71(6):772-782. PubMed ID: 29478867
[TBL] [Abstract][Full Text] [Related]
10. SIADH-related hyponatremia in hospital day care units: clinical experience and management with tolvaptan.
De Las Peñas R; Ponce S; Henao F; Camps Herrero C; Carcereny E; Escobar Álvarez Y; Rodríguez CA; Virizuela JA; López López R
Support Care Cancer; 2016 Jan; 24(1):499-507. PubMed ID: 26431960
[TBL] [Abstract][Full Text] [Related]
11. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia.
Schrier RW; Gross P; Gheorghiade M; Berl T; Verbalis JG; Czerwiec FS; Orlandi C;
N Engl J Med; 2006 Nov; 355(20):2099-112. PubMed ID: 17105757
[TBL] [Abstract][Full Text] [Related]
12. Estimating the economic impact of a half-day reduction in length of hospital stay among patients with community-acquired pneumonia in the US.
Raut M; Schein J; Mody S; Grant R; Benson C; Olson W
Curr Med Res Opin; 2009 Sep; 25(9):2151-7. PubMed ID: 19601711
[TBL] [Abstract][Full Text] [Related]
13. Effect of serum sodium concentration and tolvaptan treatment on length of hospitalization in patients with heart failure.
Cyr PL; Slawsky KA; Olchanski N; Krasa HB; Goss TF; Zimmer C; Hauptman PJ
Am J Health Syst Pharm; 2011 Feb; 68(4):328-33. PubMed ID: 21289328
[TBL] [Abstract][Full Text] [Related]
14. Hyponatremia-associated healthcare burden among US patients hospitalized for cirrhosis.
Deitelzweig S; Amin A; Christian R; Friend K; Lin J; Lowe TJ
Adv Ther; 2013 Jan; 30(1):71-80. PubMed ID: 23292659
[TBL] [Abstract][Full Text] [Related]
15. A retrospective study on tolvaptan prescription in clinical practice in patients with syndrome of inappropriate secretion of antidiuretic hormone (SIADH) using the Japanese claims database.
Hagiwara D; Matsukawa M; Tasaki J; Nakamura Y; Arima H
Endocr J; 2023 Dec; 70(12):1195-1205. PubMed ID: 37914256
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and tolerance of urea compared with vaptans for long-term treatment of patients with SIADH.
Soupart A; Coffernils M; Couturier B; Gankam-Kengne F; Decaux G
Clin J Am Soc Nephrol; 2012 May; 7(5):742-7. PubMed ID: 22403276
[TBL] [Abstract][Full Text] [Related]
17. Tolvaptan: any evidence of efficacy in SIADH?
Prescrire Int; 2010 Oct; 19(109):197-200. PubMed ID: 21180368
[TBL] [Abstract][Full Text] [Related]
18. Economic impact of hyponatremia in hospitalized patients: a retrospective cohort study.
Callahan MA; Do HT; Caplan DW; Yoon-Flannery K
Postgrad Med; 2009 Mar; 121(2):186-91. PubMed ID: 19332977
[TBL] [Abstract][Full Text] [Related]
19. Acute hospital costs after minimally invasive versus open lumbar interbody fusion: data from a US national database with 6106 patients.
Wang MY; Lerner J; Lesko J; McGirt MJ
J Spinal Disord Tech; 2012 Aug; 25(6):324-8. PubMed ID: 21685806
[TBL] [Abstract][Full Text] [Related]
20. Real-life experience of tolvaptan use in the treatment of severe hyponatraemia due to syndrome of inappropriate antidiuretic hormone secretion.
Tzoulis P; Waung JA; Bagkeris E; Carr H; Khoo B; Cohen M; Bouloux PM
Clin Endocrinol (Oxf); 2016 Apr; 84(4):620-6. PubMed ID: 26385871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
